Objective regressions in non-small cell lung cancer...

Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)

Kris, M.G, Herbst, R, Rischin, D, LoRusso, P, Baselga, J, Hammond, L, Feyereislova, A, Ochs, J, Averbuch, S
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
29
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/s0169-5002(00)80233-0
Date:
September, 2000
File:
PDF, 111 KB
english, 2000
Conversion to is in progress
Conversion to is failed